CD274 and neoplasm: Indeed, patients with no or low PD-L1 expression (TC0 and IC0) and a high blood-based tumor mutational burden score showed a trend towards a progression-free survival benefit29, and a patient with mismatch repair-deficient hepatoid adenocarcinoma of the lung was reported to respond to anti-PD-L1 therapy despite there being no PD-L1 expression in the tumor30.